Quick Answer
Compass Therapeutics, Inc. reported Research And Development Expense of $14.90 million for the year ending 2020.
- Compass Therapeutics, Inc. showed a decrease of -33.6% in Research And Development Expense from 2019 to 2020.
- This data is from Compass Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2021.
- XBRL data for this metric is available from 2019 to 2020 (2 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: $5.39 million | Q3 2019: $5.98 million | Q1 2020: $3.57 million | Q2 2020: $2.99 million | Q3 2020: $3.67 million | Q1 2021: $4.70 million.
- Historical annual values: Fiscal year 2020: $14.90 million | Fiscal year 2019: $22.45 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: